Johanna C. Bendell
A5028472820- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- PI3K/AKT/mTOR signaling in cancer
- Pancreatic and Hepatic Oncology Research
- Genetic factors in colorectal cancer
- Peptidase Inhibition and Analysis
- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Research and Treatments
- Cancer, Hypoxia, and Metabolism
- Melanoma and MAPK Pathways
- Adenosine and Purinergic Signaling
- Renal cell carcinoma treatment
- Esophageal Cancer Research and Treatment
- Chronic Lymphocytic Leukemia Research
- Advanced Breast Cancer Therapies
- Cancer therapeutics and mechanisms
- Colorectal and Anal Carcinomas
- Lung Cancer Research Studies
Sarah Cannon
2015-2024
Tennessee Oncology
2015-2024
Roche (Switzerland)
2021-2024
Eli Lilly (United States)
2016-2021
Florida Cancer Specialists & Research Institute
2021
Sarah Cannon Research Institute
2009-2020
Memorial Sloan Kettering Cancer Center
2011-2018
Cornell University
2009-2018
Canon (United States)
2009-2018
Yale Cancer Center
2011-2018
Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-instability–high (MSI-H) or mismatch-repair–deficient (dMMR) tumors after previous therapy. The efficacy of PD-1 as compared with chemotherapy first-line therapy for MSI-H–dMMR advanced metastatic colorectal cancer is unknown.
Abstract BACKGROUND Women with HER‐2 overexpressing metastatic breast carcinoma benefit from trastuzumab‐based therapy, but trastuzumab does not cross the blood‐brain barrier. The authors characterized central nervous system (CNS) disease in these women. METHODS Using pharmacy records, retrospectively identified 153 women treated alone or chemotherapy for HER‐2–positive at Dana‐Farber Partners Cancer Care June 1998 to December 2000. A study cohort of 122 patients was after excluding without...
This phase I dose-escalation study investigated the maximum-tolerated dose (MTD), safety, preliminary activity, pharmacokinetics (PK), and pharmacodynamics of BKM120, a potent highly specific oral pan-Class PI3K inhibitor.Thirty-five patients with advanced solid tumors received daily BKM120 12.5 to 150 mg. Dose escalation was guided by Bayesian logistic regression model overdose control. Assessments included archival tumor molecular status, response Response Evaluation Criteria in Solid...
Anti-tumour immune activation by checkpoint inhibitors leads to durable responses in a variety of cancers, but combination approaches are required extend this benefit beyond subset patients. In preclinical models tumour-derived VEGF limits cell activity while anti-VEGF augments intra-tumoral T-cell infiltration, potentially through vascular normalization and endothelial activation. This study investigates how blockade with bevacizumab could potentiate PD-L1 inhibition atezolizumab mRCC....
Metastatic esophagogastric cancer treatments after failure of second-line chemotherapy are limited. Nivolumab demonstrated superior overall survival (OS) versus placebo in Asian patients with advanced gastric or gastroesophageal junction cancers. We assessed the safety and efficacy nivolumab plus ipilimumab Western chemotherapy-refractory
Abstract Although BRAF inhibitor monotherapy yields response rates >50% in BRAFV600-mutant melanoma, only approximately 5% of patients with BRAFV600E colorectal cancer respond. Preclinical studies suggest that the lack efficacy is due to adaptive feedback reactivation MAPK signaling, often mediated by EGFR. This clinical trial evaluated and EGFR inhibition dabrafenib (D) + panitumumab (P) ± MEK trametinib (T) achieve greater suppression improved 142 cancer. Confirmed for D+P, D+T+P,...
To evaluate dabrafenib, a selective BRAF inhibitor, combined with trametinib, MEK in patients V600-mutant metastatic colorectal cancer (mCRC).A total of 43 mCRC were treated dabrafenib (150 mg twice daily) plus trametinib (2 daily), 17 whom enrolled onto pharmacodynamic cohort undergoing mandatory biopsies before and during treatment. Archival tissues analyzed for microsatellite instability, PTEN status, 487-gene sequencing. Patient-derived xenografts established from core biopsy samples.Of...
This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 as monotherapies in combination for patients with unresectable hepatocellular carcinoma (HCC), including a novel regimen featuring single, priming dose of (ClinicalTrials.gov identifier: NCT02519348).Patients HCC who had progressed on, were intolerant to, or refused sorafenib randomly assigned to receive T300 + D (tremelimumab 300 mg...
Patients with advanced pancreatic adenocarcinoma have a poor prognosis and limited second-line treatment options. Evidence suggests role for the Janus kinase (JAK)/signal transducer activator of transcription pathway in pathogenesis clinical course cancer.In this double-blind, phase II study, patients metastatic cancer who had experienced failure gemcitabine were randomly assigned 1:1 to JAK1/JAK2 inhibitor ruxolitinib (15 mg twice daily) plus capecitabine (1,000 mg/m(2) or placebo...
Preclinical evidence suggests that concomitant BRAF and EGFR inhibition leads to sustained suppression of MAPK signaling suppressed tumor growth in BRAFV600E colorectal cancer models. Patients with refractory BRAFV600-mutant metastatic CRC (mCRC) were treated a selective RAF kinase inhibitor (encorafenib) plus monoclonal antibody targeting (cetuximab), (n = 28) or without 26) PI3Kα (alpelisib). The primary objective was determine the maximum tolerated dose (MTD) recommended phase II dose....
Purpose Interleukin-10 (IL-10) stimulates the expansion and cytotoxicity of tumor-infiltrating CD8+ T cells inhibits inflammatory CD4+ cells. Pegylation prolongs serum concentration IL-10 without changing immunologic profile. This phase I study sought to determine safety antitumor activity AM0010. Patients Methods with selected advanced solid tumors were treated AM0010 in a dose-escalation study, which was followed by renal cell cancer (RCC) dose-expansion cohort. self-administered...
A proper estimation of the magnitude overall survival (OS) benefit from infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab versus doublets + is lacking because all trials that have investigated this regimen had primary end points other than OS. To test OS with higher power to explore interaction treatment effect main patient disease characteristics, we performed an individual data (IPD) meta-analysis.
LBA4 Background: KEYNOTE-177 (NCT02563002) is a phase 3, randomized open-label study evaluating the efficacy and safety of pembrolizumab (pembro) versus standard care chemotherapy ± bevacizumab or cetuximab (chemo) as first-line therapy for patients (pts) with microsatellite-instability high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). We present results final PFS analysis. Methods: A total 307 pts MSI-H/dMMR mCRC determined locally ECOG PS 0 1 were randomly...
Abstract Background CD73 upregulation in tumors leads to local immunosuppression. This phase I, first-in-human study evaluated oleclumab (MEDI9447), an anti-CD73 human IgG1λ monoclonal antibody, alone or with durvalumab patients advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), epidermal growth factor receptor-mutant non-small-cell lung (NSCLC). Methods Patients received 5–40 mg/kg (dose-escalation) 40 (dose-expansion) intravenously every 2 weeks (Q2W), (escalation...